ReviewPathogens (Basel, Switzerland)2021
A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development.
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Sweet syndrome induced by SARS-CoV-2 vaccines: A systematic review of patient-report studies.Human vaccines & immunotherapeutics · 2023Pooled it
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis.BMC infectious diseases · 2024Review
- A Brief Focus on SARS-CoV-2 Genomic Evolution and Vaccines.Pathogens (Basel, Switzerland) · 2023Article
- PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application.NPJ vaccines · 2023Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- The COVID-19 vaccine did not affect the basal immune response and menstruation in female athletes.Physiological reports · 2023Article
- A perspective on SARS-CoV-2 virus-like particles vaccines.International immunopharmacology · 2023Review
- Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2.Bioprocess and biosystems engineering · 2022Review
- Development of virus-like particles-based vaccines against coronaviruses.Biotechnology progress · 2022Review
- Article
- Sports Elite Means Vaccine Elite? Concerns and Beliefs Related to COVID-19 Vaccines among Olympians and Elite Athletes.Vaccines · 2022Article
- Article
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.Science advances · 2022Article
- An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).Cellular & molecular biology letters · 2022Review
- A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.Virusdisease · 2022Review
- COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.Journal of microbiology (Seoul, Korea) · 2022Review
- Recent COVID-19 vaccination has minimal effects on the physiological responses to graded exercise in physically active healthy people.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Article
- A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.Vaccine · 2022Article
- Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the beginning of 2020, the world has been in a race to develop vaccines that can control the COVID-19 pandemic. More than 250 projects have been initiated for this purpose, but only 14 of them have been authorized for use, despite being in phase 3 clinical trials. More than 40 other vaccines are also in phase 1/2 clinical trials and show promising outcomes. Regarding the appropriate choice of vaccines for each country or region, we reviewed the currently used vaccines in light of the different influencing parameters. These factors include the mode of action, dosage protocol, age group of the vaccinee, side effects, storage conditions, mounted immune response, and cost. Technically, there are seven types of vaccines developed against SARS-CoV-2: messenger RNA (mRNA), nonreplicating and replicating vectors, inactivated viruses, protein subunits, viral-like particles, DNA vaccines, and live attenuated vaccines. The mRNA type is being used for the first time in humans. Unfortunately, mutated variants of SARS-CoV-2 have started to appear worldwide, and researchers are investigating the effects of the currently used vaccines on them. There are many concerns regarding the long-term protection afforded by these vaccines and their side effects, and whether they require future modifications to be effective against the mutated variants. The development of new vaccines using more advanced technology is paramount for overcoming the difficulties in controlling the COVID-19 pandemic across the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.